Resources
Resources
Resources
Organ Regeneration and Repair
Posted by: Ira Pastor on 7/23/2011 8:11:05 AM
Funding Needed:
Above $1mil
Category:
Biotechnology
Website :
Please login to view.
Location :
Phila, Pennsylvania, USA
Viewed : 876 times
Favorited : 2 times
Share
Description:
We are developing a proprietary biologic, BQ-A, as a pharmaceutical for regeneration and repair of human organs and tissues.

When administered in-vivo, BQ-A creates tissue specific micro-environments that coordinate efficient regeneration and repair. These micro-environments mimic those seen during normal human fetal development, as well as during amphibian limb and organ regeneration.

Developed as a biologic, BQ-A will be more amenable to existing regulatory pathways than technologies such as cell therapies, and avoids flaws in the industry’s current stem cell centric approach.

With annual combined costs of organ transplantation, organ replacement, and medical care / pharmaceuticals for diseases that lead to organ failure, at over $1 trillion in the U.S. alone, BQ-A represents a lucrative opportunity, and makes Bioquark an attractive candidate for high-value strategic transactions and a public offering.

To date, Bioquark has conducted pre-clinical testing of BQ-A in animal models of both regeneration and repair, including traumatic brain injury, melanoma, skin wrinkling, and hair loss, highlighting potential across a range of tissues and administration methods.

The company is now moving forward with a plan to generate human clinical data for BQ-A within three years.
Respond
You must be a member to respond to this post. If you are a member , please login to respond.